Harrow, Inc. Royalty Expense
Harrow, Inc. (HROW) reported Royalty Expense of $180.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2024-05-13
- Harrow, Inc. royalty expense for the quarter ending 2024-03-31 was $180.00K, a 52.13% decline year-over-year.
- Harrow, Inc. royalty expense for the quarter ending 2023-03-31 was $376.00K.
- Harrow, Inc. royalty expense for the quarter ending 2021-03-31 was $232.00K, a 61.11% increase year-over-year.
- Harrow, Inc. royalty expense for the quarter ending 2020-03-31 was $144.00K, a 24.61% decline year-over-year.
- Harrow, Inc. royalty expense for fiscal 2020 was $682.00K, a 19.39% decline from fiscal 2019.
- Harrow, Inc. royalty expense for fiscal 2019 was $846.00K, a 50.80% increase from fiscal 2018.
- Harrow, Inc. royalty expense for fiscal 2018 was $561.00K.
| Period end | Royalty Expense 1 month | Royalty Expense 3 month | Royalty Expense 3 month as first filed | Royalty Expense 6 month | Royalty Expense 9 month | Royalty Expense 12 month |
|---|---|---|---|---|---|---|
| 2024-03-31 | $180.00K 10-Q · filed 2024-05-13 | |||||
| 2023-03-31 | $376.00K 10-Q · filed 2024-05-13 | |||||
| 2021-03-31 | $232.00K 10-Q · filed 2021-05-11 | |||||
| 2020-12-31 | $682.00K 10-K · filed 2021-03-08 | |||||
| 2020-03-31 | $144.00K 10-Q · filed 2021-05-11 | $318.00K derived: sum of 2 quarters · filed 2021-05-11 | $525.00K derived: sum of 3 quarters · filed 2021-05-11 | $799.00K derived: sum of 4 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $174.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $381.00K derived: sum of 2 quarters · filed 2021-03-08 | $655.00K derived: sum of 3 quarters · filed 2021-03-08 | $846.00K 10-K · filed 2021-03-08 | ||
| 2019-09-30 | $207.00K 10-Q · filed 2019-11-13 | $481.00K derived: sum of 2 quarters · filed 2019-11-13 | $672.00K 10-Q · filed 2019-11-13 | $918.00K derived: sum of 4 quarters · filed 2020-03-13 | ||
| 2019-06-30 | $274.00K 10-Q · filed 2019-08-14 | $465.00K 10-Q · filed 2019-08-14 | $711.00K derived: sum of 3 quarters · filed 2020-03-13 | $829.00K derived: sum of 4 quarters · filed 2020-03-13 | ||
| 2019-03-31 | $191.00K 10-Q · filed 2019-05-09 | $437.00K derived: sum of 2 quarters · filed 2020-03-13 | $555.00K derived: sum of 3 quarters · filed 2020-03-13 | $669.00K derived: sum of 4 quarters · filed 2020-03-13 | ||
| 2018-12-31 | $246.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $364.00K derived: sum of 2 quarters · filed 2020-03-13 | $478.00K derived: sum of 3 quarters · filed 2020-03-13 | $561.00K 10-K · filed 2020-03-13 | ||
| 2018-09-30 | $118.00K 10-Q · filed 2019-11-13 | $232.00K derived: sum of 2 quarters · filed 2019-11-13 | $315.00K 10-Q · filed 2019-11-13 | |||
| 2018-06-30 | $114.00K 10-Q · filed 2019-08-14 | $197.00K 10-Q · filed 2019-08-14 | ||||
| 2018-03-31 | $64.00K 10-K · filed 2020-03-13 | $183.00K 10-Q · filed 2019-05-09 | $64.00K 10-Q · filed 2018-05-15 | |||
| 2018-01-31 | $44.00K 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |